Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 3/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.39 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.39 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6518300 | 0.90 | AURKA (0.45) | AURKAKDRAURKBCHEK1 | |
| SCHEMBL6512223 | 0.88 | CHEK1 (0.51) | AURKAKDRAURKBCHEK1 | |
| SCHEMBL6509375 | 0.88 | AURKA (0.45) | AURKAKDRAURKBCHEK1 | |
| SCHEMBL6514590 | 0.84 | AURKA (0.46) | AURKAKDRAURKBCHEK1 | |
| SCHEMBL6519572 | 0.84 | CHEK1 (0.47) | AURKAKDRAURKBCHEK1 | |
| SCHEMBL6519853 | 0.82 | AURKA (0.44) | AURKAKDRAURKBCHEK1 | |
| SCHEMBL6510076 | 0.78 | AURKA (0.57) | AURKAKDRAURKBCHEK1 | |
| SCHEMBL6514912 | 0.77 | CHEK1 (0.55) | CHEK1 | |
| SCHEMBL6512770 | 0.77 | AURKA (0.50) | AURKAKDRAURKBCHEK1 | |
| SCHEMBL6522416 | 0.76 | MAPT (0.49) | AURKAKDRAURKBCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | REN 3593/4885TACR2 2793/4885AURKA 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.